Phase III, randomized, multicentre trial of maintenance biotherapy with interleukin-2 (IL-2) and interferon-alpha (IFN) for metastatic renal cell cancer (RCC)
Rodolfo Passalacqua(Champalimaud Foundation), Caterina Caminiti(University of Parma), Sebastiano Buti(University of Parma), Camillo Porta(University of Pavia), Matteo Dalla Chiesa(University of Bergamo), Debora Pezzuolo(University of Bergamo), Carlo Buzio(University of Bergamo), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Roberto Labianca(Ospedale Papa Giovanni XXIII), R. Camisa(University of Bergamo), Giovanni Tomasello(Tecnologie Avanzate (Italy))
Cited by 3
Related Papers
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials
|Journal of Clinical Oncology|2008|582